{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Malignancy&page=9", "query": { "condition": "Hematologic Malignancy", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 7767, "total_pages": 777, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Malignancy&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Malignancy&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T12:04:09.735Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04167917", "title": "NTX-301 in MDS/AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "NTX-301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 22, "start_date": "2021-01-06", "completion_date": "2025-04-24", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-10-20T12:04:09.735Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Milwaukee, Wisconsin", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04167917" }, { "nct_id": "NCT06876649", "title": "A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 787, "start_date": "2025-05-20", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-20T12:04:09.735Z", "location_count": 18, "location_summary": "Jacksonville, Florida • Miami, Florida • Sarasota, Florida + 15 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06876649" }, { "nct_id": "NCT02477878", "title": "Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Lymphoma", "Multiple Myeloma", "Hematologic Neoplasms" ], "interventions": [ { "name": "BPX-501", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2016-07", "completion_date": "2033-01", "has_results": false, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-10-20T12:04:09.735Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Westwood, Kansas • Buffalo, New York + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Buffalo", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02477878" }, { "nct_id": "NCT04318678", "title": "CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML/MDS", "B-ALL", "T-ALL", "BPDCN" ], "interventions": [ { "name": "CD123-CAR T", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 108, "start_date": "2020-07-29", "completion_date": "2030-07-29", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-20T12:04:09.735Z", "location_count": 2, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04318678" }, { "nct_id": "NCT00526838", "title": "Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Lymphoma" ], "interventions": [ { "name": "XL228", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2007-09", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2015-08-21", "last_synced_at": "2026-10-20T12:04:09.735Z", "location_count": 4, "location_summary": "Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00526838" }, { "nct_id": "NCT05312255", "title": "Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Plasma Cell Myeloma", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma", "Smoldering Plasma Cell Myeloma" ], "interventions": [ { "name": "Behavioral Intervention", "type": "BEHAVIORAL" }, { "name": "Beta-Adrenergic Antagonist", "type": "DRUG" }, { "name": "Propranolol", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Resistance Training", "type": "OTHER" }, { "name": "Short-Term Fasting", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2022-06-28", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2025-12-01", "last_synced_at": "2026-10-20T12:04:09.735Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05312255" }, { "nct_id": "NCT04655755", "title": "Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2021-01-19", "completion_date": "2028-07-20", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-20T12:04:09.735Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04655755" }, { "nct_id": "NCT02085408", "title": "Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Secondary Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Observation", "type": "OTHER" }, { "name": "Allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 727, "start_date": "2011-02-04", "completion_date": "2022-12-21", "has_results": true, "last_update_posted_date": "2024-12-13", "last_synced_at": "2026-10-20T12:04:09.735Z", "location_count": 266, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 181 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02085408" }, { "nct_id": "NCT03133221", "title": "1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Hodgkin Lymphoma", "Follicular Lymphoma", "Indolent Lymphoma", "B-cell Lymphoma", "Transformed Lymphoma", "Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia", "Small Lymphocytic Lymphoma", "Lymphoplasmacytic Lymphoma" ], "interventions": [ { "name": "Zydelig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2017-10-23", "completion_date": "2024-09-29", "has_results": true, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-10-20T12:04:09.735Z", "location_count": 3, "location_summary": "Miami, Florida • Baltimore, Maryland • Milwaukee, Wisconsin", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03133221" }, { "nct_id": "NCT00429416", "title": "Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "L-leucyl-L-leucine Methyl Ester (LLME)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)", "type": "BIOLOGICAL" }, { "name": "Hematopoietic stem cell transplantation (HSCT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2004-03", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-10-20T12:04:09.735Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00429416" } ] }